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BACKGROUND: Extracellular matrix metalloproteases (MMPs) have raised an extraordinary interest in cancer research because of their
potential role in basal membrane and extracellular matrix degradation, consequently facilitating tumour invasion and metastases
development.
METHODS: An immunohistochemical study was performed using tissue arrays and specific antibodies against MMPs 1, 2, 7, 9, 11, 13, 14,
and their tissue inhibitors, TIMPs 1, 2 and 3. More than 2600 determinations on cancer specimens from 133 patients with clinically
localised prostate carcinoma, 20 patients with prostatic intraepithelial neoplasia and 50 patients with benign prostate hyperplasia and
controls, were performed.
RESULTS: When compared with benign pathologies, prostate carcinomas had higher expression of all MMPs and TIMPs. Dendogram
shows a first-order division of tumours into two distinct MMPs/TIMPs molecular profiles, one of them with high MMPs/TIMs
expression profile (n¼70; 52.6%). Tumours with high expression of MMP-11 or -13, or cluster thereof, were significantly associated
with higher probability of biochemical recurrence.
CONCLUSION: The expression of MMPs and TIMPs seems to have an important role in the molecular biology of prostate carcinomas,
and their expression by tumours may be of clinical interest to used as indicators of tumour aggressiveness.
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The prevalence of prostate cancer is so high that it could be
considered as a normal age-related phenomenon (Hughes et al,
2005). Several published autopsy series have shown that up to
one-third of men between the ages of 30 and 40 years harbour
histological evidence of prostate carcinoma (Sakr et al, 1994).
A significant minority of patients undergoing radical prosta-
tectomy for clinical organ-confined disease will ultimately be
found to have pathological evidence of spread outside the prostate.
Although these patients may be expected to have progression
and survival rates comparable to those of patients with clinical
advanced clinical disease, as defined by grade and serum prostate-
specific antigen (PSA) level, those men who present with clinical
stage T3 are likely to have greater tumour volume, higher grade
and increased likelihood of regional spread. Currently, the
majority of men undergoing prostatectomy for pathologically
advanced disease are categorised as high risk on the basis of serum
PSA value or biopsy Gleason score. Nevertheless, there is some
overlap in the groups of men undergoing radical prostatectomy for
clinical stage T3 and for pathological stage T3 (Meng and Carrol,
2007).
Despite recent improvement in diagnostic and therapeutic
techniques, the survival rate of prostate cancer patients remains
poor due to post-treatment recurrence disease. Despite all the
recent efforts in the identification of molecular mechanisms
involved in the progression of prostate cancer, tumour progression
in the prostatic compartment, as well as in the metastasis
compartment, is poorly understood (Logothetis and Lin, 2005).
These pitfalls underscore the need for new risk markers that allow
the early detection of carcinogenesis and, therefore, of cancer
relapse.
Degradation of the stromal connective tissue and basement
membrane components are key elements in tumour invasion and
metastasis. This is particularly true with the interstitial collagens,
which are very resistant to proteolytic attacks, being degraded only
by matrix metalloproteinases (MMPs) (Nelson et al, 2000). The
human MMP family currently consists of 28 members of
homologous zinc-dependent endopeptidases that can be divided
into eight structural classes or, on the basis of their substrate
specificity and primary structure, into the more familiar subgroups
of collagenases (MMP-1, -8 and -13), gelatinases (MMP-2 and -9),
stromelysins (MMP-3, -10, -11), membrane-associated MMPs
(MMP-14, -15, -16, -17, -23, -24, -25) and other novel MMPs
(Brinckerhoff et al, 2000; Overall and Lopez-Otin, 2002; Demers
et al, 2005). The MMPs are synthesised as inactive zymogens,
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swhich are then predominantly activated pericellularly by either
other MMPs or by serine proteases. On the other hand, there are
available data clearly challenging the classic dogma stating that
MMPs promote metastases exclusively by modulating the remo-
delling of extracellular matrix. Indeed, MMPs have been identified
that are able to affect in vivo tumour cell behaviour as a
consequence of their ability to cleave growth factors, cell surface
receptors, cell adhesion molecules or chemokines/cytoquines
(Manes et al, 1999; Noe et al, 2001; Egeblad and Werb, 2002;
Turk et al, 2004). Furthermore, by cleaving proapoptotic factors,
MMPs are able to produce a more aggressive phenotype through
generation of apoptotic resistant cells (Fingleton et al, 2001). The
MMPs may also regulate cancer/related angiogenesis, both
positively through their ability to mobilise or activate proangio-
genic factors (Stetler-Stevenson, 1999), and negatively through
generation of angiogenesis inhibitors, such as angiostatin and
endostatin, which are cleaved from large protein precursors
(Cornelius et al, 1998). The MMPs’ activities are specifically
inhibited by the so-called tissue inhibitors of metalloproteases
(TIMPs). Currently, four different TIMPs are known to exist:
TIMPs 1, 2, 3 and 4. However, it is now assumed that TIMPs are
multifactorial proteins that are also involved in the induction of
proliferation and inhibition of apoptosis (Wurtz et al, 2005).
The expression in prostate cancer of several MMPs and TIMPs,
such as MMP-2, -7, -9, -13 and -14, TIMP-1, -2 and -3, has been
recently reported (Brehmer et al, 2003; Pang et al, 2004; Zhang
et al, 2004; Morgia et al, 2005; Riddick et al, 2005; Semaan et al,
2005; Cardillo et al, 2006). In addition, recent studies have shown
that overexpression of MMPs induces prostate tumour growth and
increases the development of metastasis (Bratland et al, 2003; Daja
et al, 2003; Cao et al, 2005, 2008; Dong et al, 2005; Lynch et al,
2005; Nabha et al, 2006; Bonfil et al, 2007; Millimaggi et al, 2007;
Pulukuri and Rao, 2008). Likewise, an association between MMPs
and/or TIMPs expression and parameters indicative of tumoural
aggressiveness or poor outcome in patients with prostate cancer
has also been reported (Gohji et al, 1998; Brehmer et al, 2003;
Trudel et al, 2003; Morgia et al, 2005; Riddick et al, 2005; Semaan
et al, 2005; Cardillo et al, 2006).
The objectives of this study were to evaluate the expression and
clinical relevance of several MMPs and TIMPs of previously
recognised biological importance in prostate carcinomas, using the
tissue array (TA) technique. This technique has allowed us the
processing of a large number of tissue specimens for a wide range
of protein determinations.
MATERIALS AND METHODS
Patients and tissues samples
The histological material used in this study was obtained from 133
patients with clinical localised prostate carcinoma (age range 44–
79 years), from 20 patients with prostatic intraepithelial neoplasia
(PIN) (age range 54–70 years) and from 50 patients with benign
prostate hyperplasia (BPH) (age range 54–70 years). We selected
patients with prostate adenocarcinomas that had undergone
radical retropubic prostatectomy and had a minimum of 5-year
follow-up in those cases that did not present a biochemical
recurrence. The exclusion criteria were the following: metastatic
disease at presentation, previous history of any type of malignant
tumour, having received any type of neoadjuvant therapy,
development of a second primary cancer and absence of sufficient
tissue in the paraffin blocks used for manufacturing TAs. From a
total of 158 patients fulfilling these criteria, we selected randomly a
sample size of 133 patients, divided in two different groups
of similar size and stratified with regard to the development
of biochemical recurrence, which was the key variable of the
study. Of these patients, 47 presented biochemical recurrence
(PSA level 40.2ngml
–1, with a second confirmatory determination).
Patients and tumour characteristics are listed in Table 1. Tumours
were staged according to the 1992 TNM classification. (Flemming
et al, 1997). Histological tumour grading was established according
to the Gleason criteria (Whitmore, 1956). The PSA serum levels
were determined, preoperatively and postoperatively, using the
‘Elecys’ immune-assay tests (Roche Diagnostic GmbH, Mannheim,
Germany). Determination of PSA serum levels was performed
1 month after surgical treatment, finding undetectable levels in all
patients. Finally, all cases were evaluated for disease recurrence or
survival status by clinical, radiological and biological examinations
every 6 months. The mean follow-up period was 62 months (range:
6–144 months). Patients were treated according to the guidelines
used in our institutions. The study adhered to national regulations
and was approved by our institution’s Ethics and Investigation
Committee.
Tissue arrays and immunohistochemistry
All radical retropubic prostatectomy specimens were routinely
fixed in 10% neutral-buffered formalin and stored after being
embedded in paraffin at room temperature from 4 months to 5
years before further testing was performed. Histopathological
representative tumour areas were defined on haematoxylin and
eosin-stained sections and marked on the slide. Tumour TA blocks
were obtained by punching a tissue cylinder (core) with a diameter
of 1.5mm through a histological representative area of each
‘donor’ tumour block, which was then inserted into an empty
‘recipient’ TA paraffin block using a manual tissue arrayer
(Beecher Instruments, Sun Prairie, WI, USA) as described
elsewhere (Parker et al, 2002). Collection of tissue cores was
carried out under highly controlled conditions. Two cores were
used for each case.
Four composite high-density TA blocks were designed, and
serial 5-mm sections were consecutively cut with a microtome
(Leica Microsystems GmbH, Wetzlar, Germany) and transferred to
adhesive-coated slides. One section from each TA block was
stained with haematoxylin and eosin, and these slides were then
reviewed to confirm that the sample was representative of the
original tumour. Immunohistochemistry was carried out on these
sections of TA fixed in 10% buffered formalin and embedded in
paraffin using a TechMate TM50 autostainer (Dako, Glostrup,
Table 1 Basal characteristics of 133 patients with prostate carcinoma
Without biochemical
recurrence
(n¼86)
With biochemical
recurrence
(n¼47)
Characteristics No. (%) No. (%) P-value
Age (year) NS
o65 52 (39.5) 28 (40.4)
465 34 (60.5) 19 (59.6)
Tumoural stage o0.0001
T2 79 (91.9) 27 (57.4)
T3–4 7 (8.1) 20 (42.6)
Gleason grading o0.003
2–4 14 (16.3) 4 (8.5)
5–6 50 (58.1) 17 (36.2)
7–10 22 (25.6) 26 (55.3)
PSA (ngml
–1) NS
o10 65 (75.6) 28 (59.6)
410 21 (24.4) 19 (40.4)
Abbreviations: NS¼not significant; PSA¼prostate-specific antigen.
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sDenmark). Antibodies for MMPs and TIMPs were obtained
from Neomarker (Lab Vision Corporation, Fremont, CA, USA).
The dilution for each antibody was established based on
negative and positive controls (1/50 for MMP-2, -7 and -14, and
TIMP-2 and -3; 1/100 for MMP-1, -9 and –13, and TIMP-1; and
1/200 for MMP-11).
Tissue sections were deparaffinised in xylene, and then
rehydrated in graded concentrations of ethyl alcohol (100, 96, 80,
70%, then water). To enhance antigen retrieval only for some
antibodies, TA sections were microwave-treated (H2800 Micro-
wave Processor, EBSciences, East Granby, CT, USA) in citrate
buffer (Target Retrieval Solution, Dako) at 991C for 16min.
Endogenous peroxidase activity was blocked by incubating the
slides in peroxidase-blocking solution (Dako) for 5min. The
EnVision Detection Kit (Dako) was used as the staining detection
system. Sections were counterstained with haematoxylin, dehy-
drated with ethanol and permanently coverslipped.
Tissue arrays analysis
For each antibody preparation studied, the location of immuno-
reactivity, percentage of stained cells and intensity were deter-
mined. All the cases were semiquantified for each protein-stained
area. An image analysis system with the Olympus (Mu ¨nster,
Germany) BX51 microscope and analysis soft (analySIS, Soft
imaging system, Mu ¨nster, Germany) was used as follows: tumour
sections were stained with antibodies according to the method
explained above and counterstained with haematoxylin. There are
different optical thresholds for both stains. Each core was scanned
with a  400-power objective in two fields per core. Fields were
selected searching for the protein-stained areas. The computer
program selects and traces a line around antibody-stained areas
(red spots correspond to higher optical thresholds), with the
remaining, non-stained areas (haematoxylin-stained tissue with
lower optical threshold) standing out as a blue background. Any
field has an area ratio of stained (red) vs non-stained areas (blue).
A final area ratio was obtained after averaging two fields. To
evaluate immunostaining intensity, we used a numerical score
ranging from 0 to 3, reflecting the intensity as follows: 0, no staining;
1, weak staining; 2, moderate staining; and 3, intense staining. Using
an Excel spreadsheet, the mean score was obtained by multiplying
the intensity score (I) by the percentage of stained cells (Liu et al,
2001) and the results were added together (total score: I PC). This
overall score was then averaged with the number of cores that were
done for each patient. If there was no tumour in a particular core,
then no score was given. In addition, for each tumour, the mean
score of two core biopsies was calculated.
Furthermore, whole-tissue sections from blocks from a subset
of ten cases for either tumour, PINs or BPH specimens, were
compared with the corresponding TA discs, regarding each MMP
and TIMP expression. Those cases were selected randomly, and the
obtained clinicopathological data were very similar to those from
the whole series. Each whole-tissue section was scanned with a
 400-power lens in ten different fields. Fields were selected
searching for the protein-stained areas, such as it was described
above.
Data analysis and statistical methods
Differences in percentages were calculated with the w
2-test.
Immunostaining score values for each protein were expressed as
median (range). Comparison of immunostaining values between
groups was made with the Mann–Whitney or Kruskal–Wallis
tests. For metastasis-free survival analysis, we used the Cox
univariate method. Cox regression model was used to examine
interactions of different prognostic factors in a multivariate
analysis. Expression profiles were analysed by unsupervised
hierarchical clustering method that organises proteins in a tree
structure, based on their similarity. Data were reformatted as
follows: –‘3’ designated negative staining, ‘3’ positive staining,
missing data were left blank. The score values were reformatted
(positive-negative) choosing the median as cutoff value. We used the
Cluster 3.0 program (average linkage, Pearson’s correlation). Results
were displayed with Treeview (Eisen et al, 1998). The SPSS 17.0
software was used for all calculations (SPSS Inc., Chicago, IL, USA).
RESULTS
More than 2600 determinations were performed on TAs from 133
patients with clinically localised prostate carcinoma, from 20
patients with PIN, from 50 patients with BPH specimens and
controls. Minimal internal variance of score data between
duplicate tissue cores from the same patients was detected in
TAs, showing a high agreement for each protein (r 40.95 and
Po0.0001, for each protein). In the validation study, there was a
total concordance in the global expression, as well as in the
intensity of immunostaining, for each MMP and TIMP between
TAs and the corresponding whole-tissue sections. In addition,
there were highly significant correlations in the immunostaining
scores between these two-paired sets (r 40.90 and Po0.0001, for
each protein).
Figure 1 shows some examples of TAs with immunostaining
for each protein evaluated. Immunostaining for all the proteins
studied was localised predominantly in tumour cells, but also in
stromal cells of a significant percentage of prostate carcinomas.
However, immunostaining for all the proteins studied was
predominantly localised in epithelial cells when prostate benign
pathologies were analysed (Figure 2).
As Table 2 shows, we first compared the crude expression of
score values for MMPs and TIMPs between PINs, HBPs and
prostate carcinomas. Prostate carcinomas had higher expression of
all MMPs and TIMPs compared with benign pathologies.
It is also noteworthy that there was a wide variability in the
immunostaining score values for each protein in prostate
carcinomas, which spread more widely than those score values
in benign pathologies (Table 2).
We also evaluated the possible relationship between MMPs
and TIMPs expressions and clinicopathological factors of prostate
carcinomas, such as age of patients, tumour stage, histological
grade and pre-treatment serum levels of PSA. Our results only
showed significant association of TIMP-1 with histological grade.
Thus, tumours with higher score values for TIMP-1 had a higher
percentage of cases with high Gleason score (score 2–4: (number
of cases (percentage) 14 (21.2); score 5–6: 31 (47); score 7–10: 21
(31.8)) compared to tumours with lower score values for TIMP-1
(score 2–4: 4(6); score 5–6 (53.7); score 7–10: 27 (40.31))
(P¼0.036).
With regard to outcome from patients with prostate carcinomas,
our results showed a significant association between score values
of MMP-11 or -13 and biochemical recurrence. Patients with
tumours showing MMP-11 or -13 score values greater than median
had a significant higher probability of biochemical recurrence than
those patients with lower MMP-11 or -13 score values (P¼0.02
and P¼0.001, respectively) (Figures 3A and B, respectively).
In addition, to identify specific groups of tumours with distinct
MMP/TIMP expression profiles the data were analysed by
unsupervised hierarchical cluster analysis. The algorithm orders
proteins on the horizontal axis and samples on the vertical
axis based on similarity of their expression profiles. When
we dichotomised cases with regard to their score values as using
the median value for each MMP or TIMPs as cutoff point
were considered, a dendogram showing a first-order division of
the tumours into two distinct MMP/TIMP molecular profiles
were obtained. In this way, one of them was designated as group 1
with a high MMPs/TIMPs expression profile (n¼70) and the other
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swas designed as group 2 (n¼63) with a low MMPs/TIMPs
expression profile (Figure 4). In addition, our results showed
significant differences in prognosis between the two groups of
patients corresponding to these two types of tumours, correspond-
ing cases with high MMPs/TIMPs expression profile tumours with
those patients with higher risk of biochemical recurrence (Table 3
and Figure 3C).
Multivariate analysis according to Cox model showed
that tumour stage (PT 3–4: relative risk, RR¼3.38; 95%
confidence interval, CI¼1.7–6.5; Po0.0001) and Gleason grading
7–10: 2.08 (1.1–3.9); Po0.05) were significantly and indepen-
dently associated with biochemical recurrence. However, this
same analysis also showed that expressions of MMP-13, as
well as clustering for score values, were also independent
Figure 2 (A) Example of immunostaining for matrix metalloproteinase (MMP)-14 in prostate benign pathology. Magnification:  200. (B) Example of
immunostaining for MMP-14 in prostate carcinoma. Magnification:  200.
Figure 1 Examples of tissue arrays (TAs) with immunostaining for each protein evaluated in prostate carcinoma. (A) Matrix metalloproteinase (MMP)-1,
(B) MMP-2, (C) MMP-7, (D) MMP-9, (E) MMP-11, (F) MMP-13, (G) MMP-14, (H) tissue inhibitors of metalloprotease (TIMP)-1, (I) TIMP-2, (J) TIMP-3,
(K) normal tissue and (L) tumour with IgG.
Table 2 Comparative analysis of the score values of expressions of metalloproteases and their inhibitors in benign prostate pathology and in prostate
carcinomas
Score values (median (range))
Factor
PIN
(n¼20)
BPH
(n¼50)
Prostate cancer
(n¼133) P-value
MMP-1 0 (0–47.9) 0 (0–62.43) 104.5 (0–245.1) Po0.001
MMP-2 0 (0–32.6) 0 (0–44.6) 42.7 (0–239.6) Po0.001
MMP-7 43.76 (0–61.4) 45.44 (0–75.7) 52.75 (0–235.5) Po0.001
MMP-9 0 (0–25.84) 0 (0–24.96) 39.33 (0–123.9) P¼0.003
MMP-11 27.27 (0–50.18) 0 (0–68.6) 111.15 (0–275.5) Po0.001
MMP-13 0 (0–40) 0 (0–50.23) 42.2 (0–151.7) Po0.001
MMP-14 0 (0–39.06) 35.46 (0–89.35) 32.9 (0–290) Po0.001
TIMP-1 0 (0–56.32) 0 (0–54.78) 33.9 (0–120.8) Po0.001
TIMP-2 0 (0–43.7) 0 (0–41.87) 52.16 (0–238.8) Po0.001
TIMP-3 24.86 (0–53.45) 28.61 (0–60.95) 43.35 (0–238.76) Po0.001
Abbreviatons: BPH¼benign prostatic hyperplasia; MMP¼matrix metalloproteinase; PIN¼prostatic intraepithelial neoplasm; TIMP¼tissue inhibitors of metalloprotease.
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sfactors associated with biochemical recurrence in patients with
prostate cancer (Table 3).
DISCUSSION
Our results clearly showed higher MMPs and TIMPs expressions in
prostate carcinomas than either in PIN or in BPH, which seems to
reflect an important mechanism in the molecular biology of
prostate cancer. Similarly, some authors found significantly higher
expressions of MMP-1, -2 and -9 in prostate cancer tissues than in
BPH tissues (Zhong et al, 2008). This seems to indicate that high
expressions of MMPs and TIMPs might identify prostate benign
lesions with risk to develop cancer or even associated to
undetected malignant lesions. Therefore, these findings could be
of importance with regard to design preventive strategies and/or
for further studies of prostate cancer prevention based on
enzymatic inhibition of the MMPs/TIMPS system. Our finding
that stromal expression was found in cancer but not in BPH, where
the MMPs were localised in glandular epithelial cells, was also
especially remarkable. We speculate that these findings may be due
to epithelial–mesenchymal transition. In this way, mesenchymal
cells may again acquire a differentiated epithelial phenotype
through a mesenchymal-to-epithelial transition, which might mean
in terms of the metastatic process.
Our data also support the biological heterogeneity of prostate
carcinomas regarding the expressions of these parameters
implicated in tumour invasion and metastasis. The MMPs are
implicated in basic processes of tumour progression, such as
degradation of basement membrane and extracellular matrix,
stimulation of cellular proliferation, cellular motility, resistance to
apoptosis and angiogenesis. Therefore, the diverse clinical evolu-
tion of prostate tumours may depend their expressions of MMPs
and TIMPs. Our results indicating an association between TIMP-1
expression and higher tumour grade were especially remarkable.
This suggests that TIMP-1 is associated with aggressive behaviour
in prostate carcinomas. If TIMPs inhibit MMPs in vivo, it should be
expected that high levels of these inhibitors would prevent tumour
progression and thus be related with low aggressiveness of
tumours. However, TIMPs are multifunctional proteins that, in
addition to its MMP-inhibitory effect, also show distinct tumour-
stimulatory functions involved in the induction of proliferation and
inhibition of apoptosis (Jiang et al, 2002; Wurtz et al, 2005).
In this study, we also investigated the possible relationship
between each one of MMPs or TIMPs expressions and clinical
outcome, such as PSA-defined recurrence after radical prosta-
tectomy in our studied population. Our results showed that the
global expression of MMP-11 and -13 by prostate carcinomas
correlated with higher incidence rate of biochemical relapse.
Therefore, the global expression of MMP-11 and -13 by prostate
carcinomas may, in combination with other factors, support
useful prognostic information for a more optimal follow-up
and treatment from these patients. Likewise, our data led us to
consider that MMP-13 and/or MMP-11 may be optimal therapeutic
targets for inhibition in prostate carcinoma. These results are in
accordance with previous studies that associated expressions of
MMP-11 or -13 with poor prognostic in other tumours, such as
breast cancer (Gonzalez et al, 2007; Vizoso et al, 2007).
The MMP-13 (collagenase-3) has been found to have an
exceptionally wide substrate specificity when compared with other
MMPs (Freije et al, 1994; Knauper et al, 1997). Moreover, it is
thought to have a central role in the MMP activation cascade, both
activating and being activated by several other MMPs (MMP-14, -2
or -3). The MMP-13 has been detected to be expressed by different
prostate cancer cell lines, prostate cancer tissue and BPH (Varani
et al, 2001; DeClerck et al, 2004; Pang et al, 2004). Its expression
pattern by prostate cells seemed to be varied according to the
malignancy of prostatic cells and, therefore, it has been suggested
to be a diagnostic marker for prostate cancer (Morgia et al, 2005).
In addition, recent report indicated that androgen acts to stimulate
the expression level of MMP-13 by LNCaP prostate cancer cell
line (Pang et al, 2004). It has also been showed that plasma
concentrations of MMP-13 were high in patients with metastasis of
prostate cancer, and in these patients decreased markedly after the
therapy began (Morgia et al, 2005).
The MMP-11 (stromalysin-3) is preferential expressed by
peritumour stromal cells (Basset et al, 1990, 1997) and high levels
of MMP-11 were associated with tumour progression and poor
prognosis in breast cancer (Chenard et al, 1996; Ahmad et al,
1998). However, at present there are few data on their expression
and clinical signification in prostate cancer. The MMP-11 is a
protease that can modulate cancer progression by remodelling
extracellular matrix. It cleaves a1-antitripsin and IGF-BP1
(Remacle et al, 2000). Normal MMP-11 expression is present
during embryogenesis and wound healing, and its expression in
stressed epithelial cells is detected in the vicinity of fibroblasts
(Boulay et al, 2001). The MMP-11 expression is observed in the
area that surrounds malignant epithelial tumour cells and some-
times in tumour cells of oesophageal, oral, papillary thyroid,
colorectal, skin and ovarian carcinomas (Thewes et al, 1999;
Mueller et al, 2000; Soni et al, 2003; Wasenius et al, 2003;
Yamashita et al, 2004). Hence, MMP-11 gene expression seems to
be associated with tumour progression (Basset et al, 1997).
On the other hand, our data also show that it is possible to
identify two phenotypes of prostate carcinomas with regard to
their global expressions of MMPs/TIMPs. One of these two groups
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Figure 3 Probability of biochemical recurrence as function of score values for matrix metalloproteinase (MMP)-11 (A), score values for MMP-13 (B) and
as function of the two mayor clusters of tumours (Groups 1 and 2) (C). Median value of score values was chosen as cutoff value.
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designed group 2 (n¼63) with low MMPs/TIMPs expression
profile. Likewise, we found a significant relationship between these
phenotypes of prostate carcinomas and biochemical recurrence.
Thus, this classification may be relevant in relation to possible
further therapies based on MMPs inhibition.
In summary, we found that MMPs/TIMPs expressions were in
general higher in prostate carcinomas than in prostate benign
tissues, which reflect an important role of these factors in the
molecular biology of prostate carcinomas. In addition, there is
variability in MMPs/TIMPs expressions in prostate carcinomas,
which support the biological heterogeneity of these tumours. In
addition, the expression of some MMPs and correlated signifi-
cantly with prognosis. Thus, our results led us to consider that
further studies on MMPs/TIMPs expressions may contribute to
understand the biological and clinical behaviour of prostate
carcinomas. In this way, further studies are needed to investigate
differential profiles of MMPs/TIMPs expressions in patients with
advanced prostate cancer that progress to hormone-refractory
prostate cancer in spite of androgen-deprivation therapy.
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Figure 4 Graphical representation of two-dimensional unsupervised
hierarchical clustering results based on immunohistochemistry expression
profiles of 10 proteins in 150 prostate carcinoma samples. Rows: samples;
columns: proteins. Protein expression scores are depicted according to a
colour scale: red: positive staining; green: negative staining; grey: missing data.
Dendogram of samples (to the left of matrix) and proteins (above matrix)
represent overall similarities in expression profiles. The status column: 1¼with
recurrence; 0¼without recurrence, at the censusp o i n t .T w om a j o rc l u s t e r so f
tumours (1 and 2) are shown for score values and in tumoural cells. The colour
reproduction of the figure is avilable on the html full text version of the paper.
Table 3 Cox univariate (HR) and multivariate (RR) analysis of the
relationship between MMPs and TIMPs expression and relapse-free survival
Factor
Event
frequency
HR
(95% CI)
RR
(95% CI)
MMP-1 21/26 1.1 (0.6–2) 1.2 (0.7–2.2)
MMP-2 28/19 0.6 (0.3–1) 0.6 (0.3–1.2)
MMP-7 18/29 1.7 (0.9–3) 1.3 (0.7–2.3)
MMP-9 19/28 1.6 (0.9–2.9) 1.2 (0.6–2.2)
MMP-11 15/32 2.5 (1.3–4.7)** 1.8 (0.9–3.4)
MMP-13 14/33 2.7 (1.4–5.2)*** 2.6 (1.4–5)**
MMP-14 18/29 1.6 (0.9–2.9) 1.5 (0.8–2.7)
TIMP-1 20/27 1.5 (0.8–2.8) 1.3 (0.7–2.5)
TIMP-2 19/28 1.5 (0.8–2.8) 1.1 (0.6–2.1)
TIMP-3 21/26 1.3 (0.7–2.3) 1.2 (0.6–2.2)
Cluster 1 vs Cluster 2 16/31 1.9 (1–3.5)* 1.7 (0.9–3.2)*
Abbreviations: CI¼confidence interval; HR¼hazard ratio; MMP¼matrix metallo-
proteinase; RR¼relative risk; TIMP¼tissue inhibitors of metalloprotease.
**Po0.005; ***Po0.001; *Po0.05.
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